Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596925 | 0.86 | NPC1 (0.52) | LMNAMEN1KMT2AMAPTTDP1 | |
| SCHEMBL3607172 | 0.84 | NAMPT (0.48) | LMNAMEN1KMT2AMAPTTDP1 | |
| SCHEMBL3617333 | 0.84 | LMNA (0.43) | LMNAMAPTTDP1ALDH1A1GAA | |
| SCHEMBL3603163 | 0.84 | LMNA (0.43) | LMNAMEN1KMT2AMAPTTDP1 | |
| SCHEMBL3612885 | 0.83 | LMNA (0.43) | LMNAMEN1KMT2AMAPTTDP1 | |
| SCHEMBL3603153 | 0.83 | LMNA (0.44) | LMNAKMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL3620990 | 0.82 | LMNA (0.43) | LMNAMEN1KMT2AMAPTTDP1 | |
| SCHEMBL3612126 | 0.81 | CNR1 (0.56) | LMNAMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3607440 | 0.81 | HSD17B10 (0.47) | LMNAMEN1KMT2AMAPTTDP1 | |
| SCHEMBL3609838 | 0.80 | SMN1; SMN2 (0.47) | LMNAMEN1KMT2AMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | claimed |
| EP-1899340-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007002368-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1899340-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007002368-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002368-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | LMNA 4613/4885MEN1 2467/4885KMT2A 2255/4885 |
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | LMNA 3908/4885MEN1 4344/4885KMT2A 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.